ERVW-1 and cancer: The development of a cancer vaccine for EOC based on HERV-K env protein functioned as TAA revealed that HERV-K env-specific cytotoxic T lymphocytes (CTLs) can elicit robust cytotoxicity towards autologous EOC cells.